September 20th 2024
Rybrevant is the first targeted second-line regimen to significantly reduce the risk of disease progression by more than 50% in patients with locally advanced or metastatic EGFR mutated non-small cell lung cancer, according to Johnson & Johnson.
Click the title above for a link to open the Pharmaceutical Executive September 2024 issue in an interactive PDF format.
Elyse Blazevich on Driving Innovation in Colorado's Thriving Life Sciences Ecosystem
Elyse Blazevich discusses the Colorado Biosciences Association’s efforts to support the state’s life sciences sector by fostering partnerships, advocating for industry growth, and building a diverse talent pipeline.
FDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis
September 16th 2024Results from the ADvocate 1, ADvocate 2, and ADhere clinical trials found that patients treated with Ebglyss 38% of patients with moderate-to-severe atopic dermatitis achieved clear or almost-clear skin after 16 weeks of treatment.
Delivery and Disruption: Navigating a Changing Care Terrain
September 16th 2024The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental innovation in engagement and access strategies.
Telehealth & Its Role in Providing Access to Weight Loss Drugs
September 16th 2024In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, share their predictions for the future of telehealth and its role in providing access to essential medications like weight loss drugs